Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$2.05 - $5.5 $4.1 Million - $11 Million
-2,000,000 Reduced 50.0%
2,000,000 $4.92 Million
Q4 2021

Feb 11, 2022

BUY
$5.92 - $9.98 $23.7 Million - $39.9 Million
4,000,000 New
4,000,000 $27.3 Million

Others Institutions Holding EQRX

About EQRx, Inc.


  • Ticker EQRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 448,140,992
  • Description
  • EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...
More about EQRX
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.